Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Data: Company filings; Chart: Axios Visuals

Sales of AbbVie's blockbuster anti-inflammatory drug Humira have declined internationally, as cheaper copycats known as biosimilars gain more traction in Europe. But Humira sales continued to rise in the U.S. last quarter because Humira biosimilars are locked out of the country until 2023.

Why it matters: Cheaper versions of Humira exist, but Americans don't have access to them due entirely to AbbVie's "legal strategy" of delaying entry.

The big picture: Humira biosimilars entered the European market in October 2018.

  • AbbVie signed deals with biosimilar manufacturers that prevent those biosimilars from entering the U.S. market until 2023.
  • Many employers have sued AbbVie, alleging the company has played games with Humira's patents and created "anticompetitive" deals to keep biosimilars out of the U.S.

Worth noting: AbbVie raised Humira's price by 7.4% at the start of this year.

  • If history is any guide, AbbVie keeps more than half of that price increase while the rest goes toward industry middlemen.

Go deeper: AbbVie's next Humira

Go deeper

19 mins ago - World

Blinken, Austin call out China at event on Australia security pact

Blinken and Austin. Photo: Andrew Harnik/POOL/AFP via Getty Images

Secretary of State Tony Blinken and Defense Secretary Lloyd Austin condemned China's "aggressive" and "destabilizing" behavior at a press conference Thursday, as they inaugurated a major new trilateral security partnership with Australia and the U.K.

Why it matters: China was not explicitly mentioned in President Biden's announcement of the AUKUS alliance, through which the U.S. and the U.K. will help Australia acquire nuclear-powered submarines as part of a broader effort to ensure "peace and stability in the Indo-Pacific."

2020 was the deadliest year for environmental defenders

Engineer Sandra Cuéllar is one of many Colombians who've gone missing or been killed for their environmental activism. Photo: Luis Robayo/AFP via Getty Images

Latin America and the Caribbean is the deadliest region for environmental defenders, a violent record that has global repercussions.

Why it matters: The region has several of the most biodiverse areas of the planet, but they are constantly threatened by logging, mining or aquifer overexploitation.

3 hours ago - Politics & Policy

Senate offices closing ahead of "Justice for J6" demonstration

Security fencing outside the U.S. Capitol ahead of a planned "Justice for J6" rally in Washington, D.C.. Photo: Stefani Reynolds/Bloomberg via Getty Images

Multiple congressional offices will be closed Friday amid security precautions ahead of Saturday's rally in support of jailed Jan. 6 rioters, aides who have been instructed to work remotely tell Axios.

Why it matters: As the U.S. Capitol faces its first large-scale security test since the deadly attack, House and Senate offices are taking precautionary measures to protect staff as well as lawmakers.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!